Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of $0.27, $0.62 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $73.4 million versus the consensus estimate of $73.86 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.